ReviewInternational journal of impotence research2021
Sexual function in men undergoing androgen deprivation therapy.
Review in International journal of impotence research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- The role of the urologist in managing high flow priapism.International journal of impotence research · 2026Review
- Chronic administration of the hydrogen sulfide prodrug SG1002 partially protects against erectile dysfunction resulting from long-term androgen deprivation.Life sciences · 2025Article
- Psychological Involvement in the Journey of a Patient with Localized Prostate Cancer-From Diagnosis to Treatment.Diseases (Basel, Switzerland) · 2025Article
- Sexual activity in men undergoing ADT for localized prostate cancer: a narrative literature review.Asian journal of andrology · 2025Review
- Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM).ESMO open · 2025Review
- Impact of neoadjuvant relugolix on patient-reported sexual function and bother.Frontiers in oncology · 2024Article
- Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.Medicina (Kaunas, Lithuania) · 2023Review
- The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian Scientific Societies, guidelines on the diagnosis and management of erectile dysfunction.Journal of endocrinological investigation · 2023Article
- Comparison of satisfaction with penile prosthesis implantation in patients with prostate cancer radiation therapy versus radical prostatectomy.Translational andrology and urology · 2023Article
- The role of male hypogonadism, aging, and chronic diseases in characterizing adult and elderly men with erectile dysfunction: a cross-sectional study.Basic and clinical andrology · 2023Article
- How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?Research and reports in urology · 2023Review
- The role of testosterone in male sexual function.Reviews in endocrine & metabolic disorders · 2022Review
- Future directions in improving sexual function for prostate cancer patients.International journal of impotence research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen deprivation therapy (ADT) has a deleterious effect on sexual functions and general well-being in men. Despite this evidence, however, patient and couple knowledge about ADT side effects as well as their management is poor. Similar considerations can be made for physician endorsement of management strategies. In this paper, we summarize and critically discuss available evidence regarding the possible associations between ADT and sexual dysfunction as well as the best therapeutical options. Preclinical data show that ADT is associated with penile contractility impairment as well as lower response to phosphodiesterase type 5 inhibitors (PDE5i). Available data indicate that ADT resulted in a five to sixfold increased risk of reduced libido and in a threefold increased risk of ED confirming the main role of testosterone in regulating sexual desire. Despite this evidence, sexuality remains an important aspect of health and well-being for men and their partner. The best therapeutical options depend on patient and couple desires and needs. When nonpenetrative erections are still possible, nonpenetrative activities should be encouraged to maintain sexual intimacy. A combined and personal educational program including the collaboration of different professional figures (including general physicians, oncologists, andrologists, sexologists, and psychologists) trained in sexual medicine is advisable in order to provide the best support to subjects undergoing ADT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.